LY3214996 had no significant effect on mRNA levels for pro-fibrotic factors in naive SAE BC, but in LPA-treated BC, LY3214996 was only able to reverse the LPA-induced increase in CTGF mRNA, but not the increase in EDN1 or PDGFB mRNAs as observed with the CREB inhibitor (Fig. 4a). The gene discussed is EDN1; the disease is breast cancer.